Skip to main content

Market Overview

Charles River: Q2 Earnings Insights


Shares of Charles River (NYSE:CRL) moved higher by 0.1% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were down 3.07% year over year to $1.58, which beat the estimate of $1.26.

Revenue of $682,584,000 up by 3.80% year over year, which beat the estimate of $641,630,000.


The upcoming fiscal year's EPS expected to be between $7.05 and $7.35.

The upcoming fiscal year's revenue expected to be between $2,817,575,000 and $2,857,000,000.

Details Of The Call

Date: Aug 05, 2020

Time: 09:30 AM

ET Webcast URL:

Recent Stock Performance

52-week high: $208.44

52-week low: $95.58

Price action over last quarter: Up 27.80%

Company Profile

Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. About half of the company's revenue comes from drug discovery and preclinical testing, and one fourth comes from the manufacturing support segment.


Related Articles (CRL)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at